Shinobi Therapeutics
South San Francisco, CA
Shinobi Therapeutics focuses on creating hypoimmune CD8αβ iPS-T cells that work with the immune system to treat cancer and other diseases. The company utilizes advanced immune evasion technology to enhance the effectiveness and accessibility of cell therapies. Shinobi's innovative approach aims to reduce costs and improve patient outcomes through durable responses and redosing capabilities.
shinobitx.comCompany Details
Founded
- 2023
Employees
- Between 20 - 50 employees
Raised
- $178,000,000
Headquarters Location
- South San Francisco, CA
Public
- No
Acquired
- No
CEO
Dan Kemp
Founders
- Tobias DeuseShin Kaneko
Company Collections
These are collections Shinobi Therapeutics is a part of. Click on the collection name to view similar companies.
Shinobi Therapeutics' Industries
Shinobi Therapeutics Headquarters Location
Total Amount Raised: $178,000,000
Shinobi Therapeutics Funding Rounds
Grant
$59,000,000
Grant Investors
AMEDSeries A
$68,000,000
Series A Investors
Mitsubishi UFJ Capital Co.YosemiteSeries A
$51,000,000
Series A Investors
Eight RoadsLife Sciences Partners (LSP)F-Prime CapitalJIC Venture Growth InvestmentsD3Astellas Venture ManagementFast Track Initiative
Shinobi Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Shinobi Therapeutics.